Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes

NCT00380653 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemias
Myelodysplastic Syndromes

Interventions

DRUG: sapacitabine

Sponsor

Cyclacel Pharmaceuticals, Inc.